

11-23-01

A

j1036 U.S. PTO
09/991119

11/13/01

**DIVISION - CONTINUATION - CONTINUATION-IN-PART
APPLICATION TRANSMITTAL FORM**

Attorney Docket No.: S225-M

Anticipated Classification Of This Application:
Class Subclass

Prior Application:
Examiner
Hayes, R.

Art Unit
1647

To the Assistant Commissioner for Patents:

This is a request for filing a ☐ continuation ☒ divisional ☐ continuation-in-part application, under 37 CFR 1.53(b), of pending prior application Serial No. 08/452,229 filed on May 26, 19 95, of Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, and Susan Bektesh for GLIAL DERIVED NEUROTROPHIC FACTOR

For CONTINUATION or DIVISIONAL APPLNs only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 1b, below, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

1. ☒ Transmitted herewith are:
☒ 99 pages of specification, 11 pages of claim(s) and 1 page of abstract, totaling 111 pages.
☒ 30 sheet(s) of drawings.
☒ 3 pages of Oath or Declaration by the applicant(s):
☐ a. Newly executed (original or copy)
☒ b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional applns. only)
☒ 13 pages of Sequence Listing; computer readable copy (identical to paper copy); sequence statement.

2. ☒ The filing fee is calculated below:

For	Number Filed		Number Extra		Rate		Fee
Total Claims	9	- 20 =	0	x	\$18.00	=	\$ 0.00
Independent Claims	3	- 3 =	0	x	\$84.00	=	0.00
Multiple Dependent Claims	0			+	\$280.00	=	0.00
Basic Fee					\$740.00	=	740.00
Total Filing Fee							\$ 740.00

3. ☒ Please charge Deposit Account No. 01-0519, in the name of Amgen Inc., in the amount of \$ 740.00. An original and one copy are enclosed.
4. ☒ Throughout the prosecution of this application, if any extension of time is necessary, please consider this a request therefor.
5. ☒ The Commissioner is hereby authorized to charge any additional filing fees which may be required by the accompanying application, any additional fees which may be required during pendency of this application as required by 37 CFR 1.16 or 1.17, or credit any overpayment to Deposit Account No. 01-0519 throughout the prosecution of this application.
6. ☒ Cancel in this application original claims 1 to 36, 39 to 40, 42 to 62 and 69 to 74 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number EL360689529USDate of Deposit. November 13, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231

Lynne Buchsbaum
Printed Name

Lynne Buchsbaum
Signature

7. ☒ Preliminarily, please amend the specification by inserting before the first line the following:

--This application is a ☐ continuation ☒ division of application Serial No. 08/452,229, filed May 26, 1995; which is a divisional of 08/182,183, filed May 23, 1994; which is a 35 U.S.C. §371 filing of PCT/US92/07888, filed September 17, 1992; which is a continuation-in-part of 07/855,413, filed March 19, 1992, now abandoned; which is a continuation-in-part of 07/788,423, filed November 6, 1991, now abandoned; which is a continuation-in-part of 07/774,109, filed on October 8, 1991, now abandoned; which is a continuation-in-part of 07/764,685, filed September 20, 1991, now abandoned; which are hereby incorporated by reference . --

8. ☐ Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file. (May only be used if signed by person authorized by § 1.138 and before payment of base issue fee.)

8a. ☒ New formal drawings are enclosed.

9. ☐ Priority of application Serial No. _____ filed on _____ in _____ (country) is claimed under 35 USC 119.

9a. ☐ The certified copy has been filed in prior application Serial No. _____ filed _____

10. ☒ The prior application is assigned of record to Amgen Inc.

11. ☒ A preliminary amendment is enclosed.


12. ☒ Also enclosed Information disclosure statement, copies of 1449 and 892 forms from parent application

13. ☒ Other Associate power of attorney.

14. ☒ The power of attorney in the prior application is to:
Amgen Inc.

- a. ☒ The power appears in the original papers in the prior application.
- b. ☐ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. ☒ Address all future communications to
Ron K. Levy
at the address below.

Signator: ☒ Assignee of complete interest
☒ Attorney or agent of record



Ron K. Levy
Attorney/Agent for Applicant(s)
Registration No. 31,539
Phone: (805) 447-2205
Date: November 13, 2001

Please send all future correspondence to:

U. S. Patent Operations/ RKL
Dept. 4300, M/S 27-4-A
AMGEN, INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799, USA



21069
PATENT TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, and
Susan Bektesh

Serial No.: Not Yet Assigned

Filed: Concurrently herewith

For: GLIAL DERIVED NEUROTROPHIC FACTOR

Docket No.: S225-M

ATTORNEY'S STATEMENT PURSUANT TO 37 CFR § 1.821(e)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


The computer readable form in the present application, Serial No. (Not Yet Assigned), is identical with that filed in Application Serial No. 08/452,229, filed May 26, 1995. In accordance with 37 CFR §1.821(e), please use the last-filed computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included for incorporation into the specification.

In addition, (1) the paper copy included in the present application and (2) the reference to the above-identified parent application and computer readable form, the undersigned verifies that the content of the paper copy of the Sequence Listing in this application and the computer readable form of the Sequence Listing submitted in the parent case are the same.

Please send all future correspondence to:

US Patent Operations/ RKL
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

Respectfully submitted,



Ron K. Levy
Attorney/Agent for Applicant(s)
Registration No.: 31,539
Phone: (805) 447-2205
Date: November 13, 2001

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number EL360689529US

Date of Deposit November 13, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

Lynne Buchsbaum
Printed Name

Lynne Buchsbaum
Signature